Vindesine Sulfate

HCID 43116CAS 59917-39-4

基本情報

標準SMILES: CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
InChIKey: COFJBSXICYYSKG-FJFFLIEUSA-N
分子式: C43H57N5O11S
平均分子量: 852 g/mol
単同位体質量: 851.37752864

概要

Vindesine sulfate is an alkaloid sulfate salt. It has a role as an antineoplastic agent. It is functionally related to a vindesine.

名称と識別子

優先名称: Vindesine Sulfate
IUPAC: methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate;sulfuric acid

名称と別名

vindesine sulfate59917-39-4EldisineVindesine sulfate saltEldesineDTXSID0049074Desacetylvinblastine amide sulfateFildesin3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate (1:1) (salt)DTXCID0029000CHEBI:322953-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate

名称をさらに表示

NSC 245467LY-099094EldisinGesidineEnisonVindesini SulfasNSC-245467Sulfate, Vindesine

データベース識別子

CAS: 59917-39-4
PubChem CID: 43116
DTXSID: DTXSID0049074
ChEMBL: CHEMBL3989543
ChEBI: CHEBI:32295
EC Number: 261-984-7

物性

構造計算による物性

極性表面積: 248 Å²
水素結合供与体数: 7
水素結合受容体数: 14
回転可能結合数: 7
重原子数: 60
形式電荷: 0
複雑度: 1,650

安全と法規制

GHS分類

GHS Classification · 4 件

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P316, P305+P354+P338, P317, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 2 (100%)

毒性情報

Treatment · 1 件

Activated charcoal binds most toxic agents and can decrease their systemic absorption if administered soon after ingestion. Immediate dilution with milk or water may be of benefit in caustic or irritant chemical ingestions. If the exposure occurred through inhalation, move patient to fresh air. Monitor for respiratory distress. If cough or difficulty breathing develops, evaluate for respiratory tract irritation, bronchitis, or pneumonitis. Administer oxygen and assist ventilation as required. Treat bronchospasm with inhaled beta2 agonist and oral or parenteral corticosteroids. in case of acute lung injury, Maintain ventilation and oxygenation and evaluate with frequent arterial blood gas or pulse oximetry monitoring. Following eye exposure, irrigate exposed eyes with copious amounts of room temperature water for at least 15 minutes. In case of dermal exposure, Remove contaminated clothing and wash exposed area thoroughly with soap and water. Treat dermal irritation or burns with standard topical therapy. Patients developing dermal hypersensitivity reactions may require treatment with systemic or topical corticosteroids or antihistamines. (T36)

Health EffectsThe bone marrow depressant effects of vindesine may result in an increased incidence of microbial infection, delayed healing, and gingival bleeding (A609).

Exposure RoutesIngestion, inhalation (T36, A566).

Toxicity SummaryVindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Toxicity DataLD50: 4 mg/kg (Mouse)

化学と産業

薬理情報

Metabolism/MetabolitesHepatic Half Life: 24 hours.

MeSH Pharmacological Classification · 2 件

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.

用途と製造

UsesVindesine is used in chemotherapy to treat many different types of cancer, including leukaemia, lymphoma, melanoma, breast cancer, and lung cancer (L1022).